Pengyu Huang
Head, In Vivo Pharmacology Simcere Pharmaceutical Group
Pengyu Huang is a senior scientific leader in oncology drug development, currently serving as Director and Head of In Vivo Pharmacology at Simcere Zaiming.
In this role, he is responsible for overseeing preclinical In-vivo pharmacology studies – including animal models and translational tumor research, that support development of novel cancer therapies. His work helps early-stage research to clinical candidates, ensuring that therapeutic products demonstrate efficacy and safety in relevant preclinical systems before advancing.
Huang’s leadship contributes to the Simcere’s broader mission of advancing innovative, translational cancer medicines from bench to bedside.
Seminars
Wednesday 13th May 2026
Balancing Toxicology & Efficacy to Design Studies That Predict Real Clinical Value
4:30 pm
- Avoid costly pipeline pivots by distinguishing regulatory-driven toxicology studies from internal proof of-efficacy experiments that determine whether a program is worth advancing
- Improve Phase 1 success rates by integrating mechanistic efficacy insights upfront, not after GLP, ensuring safety signals are interpreted in the context of therapeutic promise
- Strengthen decision-making by aligning toxicology, pharmacology, and regulatory expectations early so resource-limited programs don’t over-optimize for approval while under-investing in efficacy
